Physician profile
David H Berman
NPI 1962442517
$6,835.32
in general payments reported to CMS, 2019-2025
49 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $601 · 2021: $874 · 2022: $1,364 · 2023: $1,007 · 2024: $916 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $932.98 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $712.56 | 2019-2025 | Linzess, Qulipta, Viberzi |
| Amgen INC. | $692.82 | 2019-2023 | Repatha |
| Ferring Pharmaceuticals INC. | $445.83 | 2019-2022 | |
| Pfizer INC. | $344.51 | 2022-2025 | |
| Novo Nordisk INC | $327.42 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $253.62 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $250.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.95 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.53 | 2019-2023 | Trulance |
| Biogen, INC. | $191.78 | 2021-2022 | |
| Lilly USA, LLC | $152.69 | 2022-2025 | Mounjaro, Kisunla, Zepbound |
| Intercept Pharmaceuticals, INC. | $144.34 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $137.35 | 2019 | |
| Celgene Corporation | $120.76 | 2021-2023 | Zeposia |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.